---
layout: post
title: "Revising Abbreviated New Drug Application Labeling Following Revision of the Reference Listed Drug Labeling; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:57:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-01577
original_published: 2022-01-27 00:00:00 +0000
significance: 8.00
---

# Revising Abbreviated New Drug Application Labeling Following Revision of the Reference Listed Drug Labeling; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 27, 2022 00:00 UTC
**Document Number:** 2022-01577

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Revising ANDA Labeling Following Revision of the RLD Labeling." This guidance provides recommendations for updating labeling for abbreviated new drug applications (ANDAs) following revisions to the labeling of a reference listed drug (RLD), including information on how to identify RLD labeling updates and how to submit labeling updates to both unapproved and approved ANDAs to conform to RLD labeling updates. This draft guidance revises the guidance for industry entitled "Revising ANDA Labeling Following Revision of the RLD Labeling" issued in April 2000.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/27/2022-01577/revising-abbreviated-new-drug-application-labeling-following-revision-of-the-reference-listed-drug)
- API: https://www.federalregister.gov/api/v1/documents/2022-01577

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
